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Hematopoietic SCT in Europe 2013: recent trends in the
use of alternative donors showing more haploidentical
donors but fewer cord blood transplants
JR Passweg1, H Baldomero1, P Bader2, C Bonini3, S Cesaro4, P Dreger5, RF Duarte6, C Dufour7, JHF Falkenburg8,
D Farge-Bancel9, A Gennery10, N Kröger11, F Lanza12, A Nagler13, A Sureda6 and M Mohty14 for the European Society for Blood and
Marrow Transplantation (EBMT)
A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43%) and 19 859 autologous (57%)) were reported by 658
centers in 48 countries to the 2013 survey. Trends include: more growth in allogeneic than in autologous HSCT, increasing use of
sibling and unrelated donors and a pronounced increase in haploidentical family donors when compared with cord blood donors
for those patients without a matched related or unrelated donor. Main indications were leukemias, 11 190 (32%; 96% allogeneic);
lymphoid neoplasias, 19 958 (57%; 11% allogeneic); solid tumors, 1543 (4%; 4% allogeneic); and nonmalignant disorders, 1975 (6%;
91% allogeneic). In patients without a matched sibling or unrelated donor, alternative donors are used. Since 2010 there has been a
marked increase of 96% in the number of transplants performed from haploidentical relatives (802 in 2010 to 1571 in 2013),
whereas the number of unrelated cord blood transplants has slightly decreased (789 in 2010 to 666 in 2013). The use of donor type
varies greatly throughout Europe.
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INTRODUCTION
Hematopoietic SCT (HSCT) is an established procedure for many
acquired and congenital disorders of the hematopoietic system,
including disorders of the immune system, and as enzyme
replacement in metabolic disorders.1–4 The annual activity survey
of the European Society of Blood and Marrow Transplantation
(EBMT), describing the status of HSCT in Europe and affiliated
countries, has become an instrument used to observe trends and
to monitor changes in technology use.5–10 The survey captures the
numbers of HSCT performed in the preceding year from each
participating team, divided by indication, donor type and stem cell
source. The standardized structure of the survey over many years
and the excellent commitment of the participating teams allow us
to observe changes over time and to evaluate factors associated
with these changes. More recently, the survey has included
additional information on novel cell therapies with hematopoietic
stem cells for non-hematopoietic use, as well as on the use of non-
hematopoietic stem and progenitor cells.11 This coincides with the
recent interest of the WHO (www.who.org) in cell and tissue
transplants and further stresses the need for adequate and timely
information.12 The analysis of the survey data spanning over 20
years has shown a continued and constant increase in the annual
numbers of HSCT and transplant rates (number of HSCT per 10
million inhabitants) for both allogeneic and autologous HSCT.
This report is based on the 2013 survey data. In addition to
transplant rates and indications, this report focuses on the use of
donors other than HLA-identical siblings and matched unrelated
donors for allogeneic HSCT.
PATIENTS AND METHODS
Data collection and validation
Participating teams were invited to report data for 2013 by indication, stem
cell source and donor type as listed in Table 1. The survey allows the
possibility to report additional information on the numbers of subsequent
transplants performed as a result of relapse, rejection or those that are part
of a planned sequential transplant protocol. Supplementary information
on the numbers of DLIs, reduced intensity HSCT and the numbers of
pediatric HSCT is also collected. Quality control measures included several
independent systems: confirmation of validity of the entered data by the
reporting team, selective comparison of the survey data with MED-A data
sets in the EBMT Registry database, cross-checking with the National
Registries.
Teams
Six hundred and eighty-seven centers from 48 countries were contacted
for the 2013 survey (39 European and 9 affiliated countries); of which
658 teams reported. This corresponds to a 96% return rate and includes
551 active EBMT member teams. Twenty nine teams failed to report
in 2013.
Contacted teams are listed in the Supplementary appendix in
alphabetical order by country, city, EBMT centre code, with their reported
numbers of first and total HSCT, and of first allogeneic and autologous
HSCT. The WHO regional office definitions (www.who.org) were used to
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classify countries as European or Non-European. Nine non-European
countries participated in the 2013 EBMT survey: Algeria, Iran, Israel, Jordan,
Lebanon, Nigeria, Saudi Arabia, South Africa and Tunisia. Their data from
26 actively transplanting teams make up 6.2% of the total data set and is
included in all analyses.
Definitions
Patient and transplant numbers. Wherever appropriate, patient numbers
corresponding to the number of patients receiving a first transplant and
transplant numbers reflecting the total number of transplants performed
are listed.
The term sibling donor includes HLA-identical siblings and twins but not
siblings with HLA mismatches. Unrelated donor transplants includes HSCT
from unrelated donors with PB and bone marrow as a stem cell source but
not cord blood HSCT, these are shown as cord blood HSCT in Figures 3–5.
Mismatched family donors are termed ‘haploidentical’ for the purpose of
this analysis but this category includes also mismatched related donors
that are mismatched to a lesser degree than a full haplotype. As the
haplotype mismatched donors are the vast majority in this category, the
term ‘haploidentical’ is used for the entire group.
Multiple transplants may include multiple transplants defined as
subsequent transplants within a planned double or triple autologous or
allogeneic transplant protocol, and retransplants (autologous or allo-
geneic) defined as unplanned HSCT for rejection or relapse after a
previous HSCT.
Information on additional cellular therapies was subdivided into: HSC for
non-hematopoietic use; non-hematopoietic stem cell therapies; MSC
therapies for rejection or GVHD prevention/treatment; and DLIs. Collection
of information was validated by cross-checking with a similar more
detailed survey carried out by TERMIS-EU (Tissue Engineering and
Regenerative Medicine International Society; www.termis.org), EULAR
(European League against Rheumatism; www.eular.org), ICRS-EU (Interna-
tional Cartilage Repair Society; www.cartilage.org) and ISCT (International
Society of Cellular Therapy; www.celltherapysociety.org).11
Transplant rates. Transplant rates, defined as the total number of HSCT
per 10 million inhabitants, were computed for each country without
adjustments for patients who crossed borders and received their HSCT in a
foreign country. Population numbers were obtained from Eurostats for the
European countries (http://epp.eurostat.ec.europa.eu/portal/page/portal/
statistics/search_database) and the US census bureau database for the
non-European countries (http://www.census.gov/population/international/
data/idb/rank.php).
Analysis. Wherever appropriate, absolute numbers of transplanted
patients, transplants or transplant rates are shown for specific countries,
indications or transplant techniques.
RESULTS
2013 data
Participating teams in 2013. Of the 658 teams, 406 (62%)
performed both allogeneic and autologous transplants; 225
(34%) restricted their activity to autologous HSCT only, and 17
teams (3%) to allogeneic transplants only. Ten teams (1%)
reported having performed no transplants in 2013 owing to
renovation or temporary closure of the transplant unit. Of the 648
active centers, 120 (19%) centers performed transplants on both
adult and pediatric patients. An additional 105 (16%) centers were
dedicated pediatric transplant centers, and 423 (65%) centers
performed transplants on adults only.
Numbers of patients and transplants. A total of 34 809 patients
received their first transplant in 2013. Of these, 14 950 (43%) were
allogeneic and 19 859 (57%) autologous. When compared with
2012, the total number of patients transplanted increased by 3.4%
(5.5% allogeneic HSCT and 1.8% autologous HSCT).10 Furthermore,
there were 2710 retransplants (1162 allogeneic and 1548
autologous) and 1690 multiple transplants (99 allogeneic and
1591 autologous), bringing the total to 39 209 HSCT procedures,
16 211 allogeneic (41%) and 22 998 autologous (59%) performed
in 2013, which is an increase of 26% compared with 5 years and
88% compared with 15 years previously.
Indications for HSCT in 2013 are listed in detail in Table 1. The
main indications were leukemias; 11 190 (32% of total; 96% of
which were allogeneic); lymphoid neoplasias including Non-
Hodgkin lymphoma, Hodgkin lymphoma and plasma cell dis-
orders, 19 958 (57%; 11% allogeneic); solid tumors, 1543 (4%; 4%


































Figure 1. Relative proportions of indications for an HSCT in Europe in 2013. (a) Proportions of disease indications for an allogeneic HSCT in
Europe in 2013. (b) Proportions of disease indications for an autologous HSCT in Europe in 2013.
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allogeneic). As seen in previous years, the majority of HSCT for
lymphoid malignancies were autologous, whereas most trans-
plants for leukemia were performed using stem cells from
allogeneic donors. Autologous HSCT for nonmalignant disorders
predominantly include patients with autoimmune disorders.
Distributions of indications for HSCT are shown in
Figures 1a and b for allogeneic and autologous HSCT, respectively.
Compared with 2012, there were increases in allogeneic
HSCT for AML in CR1 (10.7%), MPN (11.1%) and NHL (12.5%). For
autologous HSCT, there was a decrease in activity for AML
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Figure 2. Transplant rates in Europe (= total number of HSCT per 10 million inhabitants) by participating country, showing 15-year trends
1998–2013. (a) Allogeneic transplant rates per 10 million population in 1998–2013 (b) Autologous transplant rates per 10 million population in
1998–2013.
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(18%) and HD (10%) but an increase for plasma cell disorders
by 6.1%.
DLIs. 2513 patients received treatment with DLIs, a 12% increase
since 2012.
Reduced intensity conditioning. 6534 of the total allogeneic HSCT
were performed using non myeloablative conditioning. This is an
increase of 11.4% since 2012 and is 40% of all allogeneic HSCT.
Fifteen year trends
Figures 2a and b show transplant rates by country for allogeneic
and autologous HSCT comparing rates in 2013 to rates 15 years
ago, to 1998. Median transplant rates per 10 million inhabitants
were 124 (range, 0.1–493) for allogeneic HSCT and 233 (range,
1.0–538) for autologous HSCT in 2013 as compared with 89 and
164 in 1998.
Figure 3a shows the 15-year trends for allogeneic and
autologous HSCT showing some narrowing in the difference
between autologous and allogeneic HSCT performed.
Figure 3b shows trends for allogeneic HSCT over the past 15
years for sibling donor and unrelated donor transplantation, with
more unrelated donor HSCT since 2007 as compared with sibling
donor HSCT, unrelated donor HSCT accounting for (53% of all
allogeneic HSCT)% in 2013.13 Figure 3c shows trends in the use of
alternative donor transplantation, separately for cord blood and
for haploidentical family donor HSCT. It is obvious that the use of
cord blood has stabilized in 2011 and is going down slightly; the
number of haploidentical HSCT has more than doubled since
2010. For haploidentical HSCT, marrow is used in 37% and PB in
63% as a stem cell source14,15 in 2013.
Figures 4a–d depict the indications for allogeneic HSCT
separately for sibling donor, unrelated donor, cord blood donor
and haploidentical donor HSCT in 2013. When comparing
leukemias, lymphoid neoplasias and nonmalignant disorders,
distributions of indications do not differ greatly; except for
nonmalignant disorders receiving more commonly cord blood
transplants, reflecting the younger age of these patients and the
preference for cord blood in children.
Figure 5 shows transplant rates for the 15 countries with the
highest rates of allogeneic HSCT in Europe ordered by decreasing
rate of unrelated donor HSCT. This figure shows considerable
heterogeneity in the use of HSCT technology among countries.
Additional cellular therapies
Seventeen teams from 11 countries reported having treated 130
patients with hematopoietic stem cells for non-hematopoietic use
in 2013. All therapies were performed using autologous HSC’s. The
main indications were cardiovascular, 75; neurological, 32; tissue
repair, 20; and epithelial, 3. In addition, 405 patients in 86 teams
and 21 countries received mesenchymal stromal cells for
prevention/treatment of GVHD (344), prevention/treatment of
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Figure 3. Absolute numbers by transplant and donor type 1998–2013. (a) Absolute numbers of allogeneic and autologous HSCT in Europe in
1998–2013. (b) Absolute numbers of sibling donor and unrelated donor HSCT in Europe 1998–2013. (c) Absolute numbers of haploidentical
and cord blood HSCT in Europe 1998–2013.
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DISCUSSION
The EBMT activity survey has been conducted annually since
1990.6 The 2010 survey reported for the first time in more than
30 000 patients transplanted in a given year.16 This trend continues
with an additional increase by 3.6% in 2013, suggesting that HSCT
remains an increasingly important treatment modality in the era of
targeted antibody and molecular therapy. The present 2013 report
focuses on allogeneic transplants using different types of donors.
HSCT for some indications continues to increase but not for
others. Of interest is growth of allogeneic HSCT for AML in CR1,
MPN and lymphoma. For autologous HSCT, the number of
transplants for myeloma continues to increase. In autologous
HSCT, the numbers of procedures for AML in CR1 and for
Hodgkin's lymphoma dropped slightly. The decrease in auto-
logous HSCT for Hodgkins Lymphoma of 10% may be related to
the availability of monoclonal antibodies in this disease.
Notable in this year's survey is the increase in the use of
allogeneic HSCT more than autologous HSCT and the increasing
use of alternative donor transplants, where an impressive trend for
more haploidentical HSCT has been observed. The category of
haploidentical HSCT as used for this analysis includes haploiden-
tical HSCTs as well as mismatched family donor HSCTs, where the
mismatch does not include a full haplotype, for example, 1 or 2
allele mismatched relatives. Unfortunately we do not have the
data to separate these categories but we think it is unlikely that
the increase observed could be explained by one allele
mismatched siblings. The increase in haploidentical HSCT coin-
cides with the publications of the post-transplant CY GVHD
prophylaxis in haploidentical HSCT.14 Again we do not have the
data within this survey to separate haploidentical HSCTs using this
strategy from other ways to perform haploidentical HSCT.
This is accompanied by a slight decrease in HSCT using
cord blood pointing to the fact that mismatched unrelated cord
blood and haploidentical donors are in competition for patients in
whom no sibling or matched unrelated donor has been
identified.14,5,17
When comparing the use of donors for allogeneic HSCT in
countries with high transplant rates, it is obvious that there are
important differences. Some may be explained by availability of
sibling donors as there are differences in family size across Europe.
There are, however, threefold differences in transplant rates for
sibling and unrelated donor HSCT among countries and even
larger differences in the use of unrelated cord blood and




























































Figure 4. Disease indications by donor type in 2013. (a) Proportions of disease indications in 2013 for sibling donor HSCT. (b) Proportions of
disease indications in 2013 for haplo-identical donor HSCT. (c) Proportions of disease indications in 2013 for unrelated donor HSCT.
(d) Proportions of disease indications in 2013 for cord blood HSCT.
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issues as well as differences in the interpretation of results of
recent studies and local experience.
Overall, this paper reflects current practice, and results may be
useful to health care planning and health policy makers.
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Sibling Unrelated Haplo-identical Cord
TR Allo 387 494 275 257 275 372 215 308 200 253 260 288 230 283 252
Figure 5. Transplant rates for sibling donor, unrelated donor, haploidentical donor and cord blood HSCT in Europe in 2013 for the 15 countries
with the highest transplant rates.
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